Team:Brown/Project Implications
From 2009.igem.org
(Difference between revisions)
(→Human Practices) |
|||
Line 7: | Line 7: | ||
=Human Practices= | =Human Practices= | ||
- | ==Safety Issues== | + | == Safety Issues == |
[[Image:Staphylococcus_epidermidis_biofilm.jpg|200px|thumb|right|Staphylococcus epidermidis biofilm]] | [[Image:Staphylococcus_epidermidis_biofilm.jpg|200px|thumb|right|Staphylococcus epidermidis biofilm]] | ||
This project raises safety issues due to the use of Staphylococcus epidermidis for producing and secreting the histamine binding protein, EV131. Although S. epidermidis is one of the more benign species of Staphylococcus, it can form infectious biofilms that are impervious to antibiotic treatment if its cell density becomes too great. This could pose a grave risk to researchers involved and the public for whom Allergene aims to serve. | This project raises safety issues due to the use of Staphylococcus epidermidis for producing and secreting the histamine binding protein, EV131. Although S. epidermidis is one of the more benign species of Staphylococcus, it can form infectious biofilms that are impervious to antibiotic treatment if its cell density becomes too great. This could pose a grave risk to researchers involved and the public for whom Allergene aims to serve. |
Revision as of 03:15, 21 October 2009
Human Practices
Safety Issues
This project raises safety issues due to the use of Staphylococcus epidermidis for producing and secreting the histamine binding protein, EV131. Although S. epidermidis is one of the more benign species of Staphylococcus, it can form infectious biofilms that are impervious to antibiotic treatment if its cell density becomes too great. This could pose a grave risk to researchers involved and the public for whom Allergene aims to serve.